A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn’s Disease Treated with Adalimumab or InfliximabReportar como inadecuado




A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn’s Disease Treated with Adalimumab or Infliximab - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Advances in Therapy

, Volume 33, Issue 11, pp 1947–1963

First Online: 23 September 2016Received: 14 June 2016DOI: 10.1007-s12325-016-0406-6

Cite this article as: Yokoyama, K., Yamazaki, K., Katafuchi, M. et al. Adv Ther 2016 33: 1947. doi:10.1007-s12325-016-0406-6

Abstract

IntroductionCrohn’s disease CD is a chronic and progressive disease in which the long-term management is important. This study sought to assess treatment persistence and dose escalation in the maintenance phase with adalimumab ADA or infliximab IFX in a Japanese real-world setting.

MethodsA retrospective analysis was conducted using the Japan Medical Data Center database. CD patients with either ADA or IFX prescriptions between January 2012 and February 2015 were included. Outcomes of interest were 1 failure in the induction phase defined as switch or discontinuation and 2 persistence in the maintenance phase defined as the absence of switch or discontinuation over 12 months since maintenance initiation.

ResultsOverall, 133 patients 53 ADA; 80 IFX were included. Of them, treatment failed in 26 patients 19.6% in the induction phase. During the induction phase, there was a trend towards fewer treatment failures with ADA than IFX 88.7% vs. 75.0%; p = 0.051. Of those who completed induction, 64 patients 33 ADA; 31 IFX had at least 12 months of valid insurance enrolment after the initiation of maintenance and 13 5 ADA; 8 IFX had either switch or discontinuation within 12 months after the initiation of maintenance. Probabilities of switch or discontinuation over 12 months after the maintenance date were 15.2% and 20.9% for ADA and IFX groups, respectively p-log rank = 0.7764.

ConclusionJapanese patients have a high primary response to anti-tumor necrosis factor therapy in the real-world setting, in line with the results of clinical trials. This initial therapeutic advantage can be lost during the maintenance phase, leading to dose escalation, treatment switch, or discontinuation. This study suggests that those events occurred in comparable proportions of patients treated with either ADA or IFX. However, these findings should be considered with caution given the retrospective nature and small size of the study.

FundingAbbvie GK, Tokyo, Japan.

KeywordsAdalimumab Anti-TNF Crohn’s disease Discontinuation Dose escalation Gastroenterology Infliximab Persistence Switch Enhanced contentTo view enhanced content for this article go to http:-www.medengine.com-Redeem-9E76F06048096649.

Electronic supplementary materialThe online version of this article doi:10.1007-s12325-016-0406-6 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Autor: Kaoru Yokoyama - Kiyotaka Yamazaki - Miiko Katafuchi - Sameh Ferchichi

Fuente: https://link.springer.com/



DESCARGAR PDF




Documentos relacionados